{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:07:57Z","timestamp":1789103277549,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02240-x","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:03:58Z","timestamp":1784041438000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world efficacy and safety of SGLT2 inhibitor add-on triple therapy in south indian patients with type 2 diabetes mellitus: a 24-week prospective observational cohort study"],"prefix":"10.1186","volume":"18","author":[{"given":"Ananya","family":"Ginjupalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeram","family":"Thiriveedhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan Sai","family":"Nelluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sravanth Reddy","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitanjali","family":"Boppana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6466-7874","authenticated-orcid":false,"given":"Suman","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"7","key":"2240_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","volume":"11","author":"RM Anjana","year":"2023","unstructured":"Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474\u201389.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2240_CR2","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.","edition":"10"},{"key":"2240_CR3","first-page":"163","volume":"57","author":"A Misra","year":"2009","unstructured":"Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India. 2009;57:163\u201370.","journal-title":"J Assoc Physicians India"},{"issue":"4","key":"2240_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MED.0000000000000166","volume":"22","author":"VN Shah","year":"2015","unstructured":"Shah VN, Mohan V. Diabetes in India: what is different? Curr Opin Endocrinol Diabetes Obes. 2015;22(4):283\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"2240_CR5","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.4103\/ijo.IJO_1627_21","volume":"69","author":"R Pradeepa","year":"2021","unstructured":"Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932\u20138.","journal-title":"Indian J Ophthalmol"},{"issue":"12","key":"2240_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.59556\/japi.71.0422","volume":"71","author":"AK Singh","year":"2023","unstructured":"Singh AK, Misra A, Bajaj S, Bhatt SP, Gupta A, Gupta S, et al. SGLT2i as first-line antihyperglycemic in the management of type 2 diabetes in the context of Indians: a systematic review and consensus. J Assoc Physicians India. 2023;71(12):62\u201371.","journal-title":"J Assoc Physicians India"},{"issue":"10","key":"2240_CR7","first-page":"1052","volume":"143","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2021;143(10):1052\u201367.","journal-title":"Circulation"},{"issue":"22","key":"2240_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"2240_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"1","key":"2240_CR10","first-page":"14","volume":"24","author":"M John","year":"2020","unstructured":"John M, Gopinath S, Kalra S. SGLT2 inhibitors in India: a review of real-world evidence. Indian J Endocrinol Metab. 2020;24(1):14\u20139.","journal-title":"Indian J Endocrinol Metab"},{"issue":"3","key":"2240_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2105\/AJPH.94.3.361","volume":"94","author":"DC Des Jarlais","year":"2004","unstructured":"Des Jarlais DC, Lyles C, Crepaz N, TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health. 2004;94(3):361\u20136.","journal-title":"Am J Public Health"},{"issue":"20","key":"2240_CR12","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"9","key":"2240_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2240_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/dom.12244","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Mannucci E. Effects of SGLT-2 inhibitors on glycaemic control and body weight: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2014;16(5):457\u201366.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2240_CR15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.2337\/diacare.26.5.1380","volume":"26","author":"C Snehalatha","year":"2003","unstructured":"Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in Asian Indian adults. Diabetes Care. 2003;26(5):1380\u20134.","journal-title":"Diabetes Care"},{"issue":"6","key":"2240_CR16","first-page":"1524","volume":"37","author":"J Bolinder","year":"2014","unstructured":"Bolinder J, Ljunggren \u00d6, Johansson L, Wilding J, Langkilde AM, Sj\u00f6str\u00f6m CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Care. 2014;37(6):1524\u201331.","journal-title":"Diabetes Care"},{"issue":"4","key":"2240_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","volume":"8","author":"WL Baker","year":"2014","unstructured":"Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose cotransporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262\u201375.","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"2240_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZI Cherney","year":"2014","unstructured":"Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587\u201397.","journal-title":"Circulation"},{"issue":"24","key":"2240_CR19","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"6","key":"2240_CR20","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1185\/03007995.2014.890925","volume":"30","author":"P Nyirjesy","year":"2014","unstructured":"Nyirjesy P, Sobel JD, Fung A, Bossart M, Gold ME, Capuano G, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014;30(6):1109\u201319.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"2240_CR21","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"8","key":"2240_CR22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (EMPALI trial). Diabetes Care. 2018;41(8):1801\u20138.","journal-title":"Diabetes Care"},{"issue":"21","key":"2240_CR23","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2240_CR24","first-page":"S1","volume":"46","author":"American Diabetes Association Professional Practice Committee","year":"2023","unstructured":"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes\u20142023. Diabetes Care. 2023;46(Suppl 1):S1\u2013291.","journal-title":"Diabetes Care"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02240-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02240-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:55:38Z","timestamp":1789102538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02240-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2240"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02240-x","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"23 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Ethics Committee. Written informed consent was obtained from all patients prior to their participation, following a full and detailed explanation of the study\u2019s purpose, procedures, and potential risks. All study protocols were conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and agreed to the published version of the manuscript. All authors agree to be accountable for all aspects of the work, ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":2,"name":"Ethics","label":"ICMJE declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for the publication of anonymized, aggregated clinical data was obtained from all participants as part of the primary consent process.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"200"}}